Purple Biotech

Tumor-immune Evasion and Drug Resistance Therapies

Health Tech & Life Sciences
Public on TASE on Jul, 2013
Public on NASDAQ on Nov, 2015

Company Overview

Snapshot

Founded in August 1968, Purple Biotech operates with 11–50 employees and has raised a total of $94.6 million across 11 funding rounds from 2 investors. The company went public on NASDAQ in November 2015.

Business overview

Purple Biotech is a clinical-stage company focused on developing first-in-class therapies designed to overcome tumor immune evasion and drug resistance. The company's oncology pipeline includes NT219, a dual inhibitor targeting IRS1/2 and STAT3; CM24, a humanized monoclonal antibody blocking CEACAM1; and IM1240, a preclinical, conditionally-activated tri-specific antibody. Purple Biotech serves the pharmaceutical and life sciences industries, operating within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In September 2025, Purple Biotech announced the closing of a public offering for up to $18 million, including an initial $6 million upfront and an additional $12 million from potential warrant exercises. This public offering demonstrates continued investor confidence and provides capital to advance its clinical-stage oncology pipeline, signaling a strong focus on accelerating drug development and commercialization efforts.

Company Intelligence Q&A

What was a significant recent financial event for Purple Biotech?
In September 2025, Purple Biotech announced the closing of a public offering for up to $18 million, comprising $6 million upfront and an additional $12 million from potential warrant exercises.
What is the status of Purple Biotech's NT219 clinical trial?
In September 2020, Kitov (now Purple Biotech) announced the dosing of the first patient in a Phase 1/2 clinical trial of NT219 for advanced cancer patients. The company is advancing NT219 as a monotherapy for solid tumors and in combination with cetuximab for recurrent and metastatic squamous cell carcinoma of the head and neck or colorectal adenocarcinoma.
What intellectual property milestones has Purple Biotech achieved for its oncology assets?
In September 2020, Kitov Pharma (now. Additionally, in October 2020, the company received a notice of allowance for a U.S. patent covering its anti-cancer drug candidate, NT219.
What is the latest development regarding Purple Biotech's CAPTN-3 platform?
In October 2025, Purple Biotech achieved a manufacturing milestone for IM1240, a tri-specific antibody from its CAPTN-3 platform. This follows the unveiling of the CAPTN-3 Cancer Therapy platform in October 2024 and new data presentations for the platform at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
What was a key acquisition made by Purple Biotech?
In February 2023, Purple Biotech acquired Immunorizon, a company focused on tri-specific antibodies, in a deal reported to be up to $100 million.

External links